Inceptua Group
https://www.inceptua.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inceptua Group
Deal Watch: Celgene CVR From BMS Buyout Falls Through
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
- Services
- Contract Manufacturing Organization
- Other Names / Subsidiaries
-
- Inceptua S.A.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice